NEW YORK--(BUSINESS WIRE)--The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared an increase of 2.6% percent in the company’s quarterly dividend, beginning in the first quarter of 2018.
The dividend increase will result in a quarterly dividend of 40 cents ($0.40) per share on the $.10 par value Common Stock of the corporation. The next quarterly dividend will be payable on February 1, 2018, to stockholders of record at the close of business on January 5, 2018.
The directors also declared a quarterly dividend of fifty cents ($0.50) per share on the $2.00 Convertible Preferred Stock of the corporation, payable March 1, 2018 to stockholders of record at the close of business on February 6, 2018.
The directors indicated an expected dividend for the full year of 2018 of $1.60 per share on the $.10 par value Common Stock of the corporation, subject to the normal quarterly review by the Board.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the Board will approve a quarterly dividend in future quarters or that the dividend for the full year of 2018 will be the amount indicated in this press release. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2016, in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.